MaxCyte Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.28next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Strategic Platform License (SPL) Partnerships Quarterly29.0Target: Add 3-5 new SPLs annually
Core Revenue Quarterly6.2MTarget: 25,000,000 to 27,000,000
Total Cash, Cash Equivalents, and Investments Quarterly147.7MTarget: At least 136,000,000 by end of 2026
Watch Items
- Core Revenue Stabilization and RecoveryTrigger: Core revenue falling below $6.0 million per quarter or failing to show second-half weightingAction: Re-evaluate commercial strategy, field sales deployment, and instrument placement targets.
- SPL Partner Clinical Progress and MilestonesTrigger: Delays in clinical trials or failure of partners to transition to registrational trialsAction: Adjust SPL milestone revenue forecasts and reassess long-term royalty pipeline expectations.
Research as of 20 Jun 2026